THE DEAL, AT A GLANCE
From the announcementArvinas
01Who is involvedBacked by VariousFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗02What happenedArvinas raised $150M Growth RoundFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03Why it mattersArvinas is positioned around targeted protein degradation in cancer, using PROTACs to eliminate disease-linked proteins rather than block them.From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
Arvinas · Financing Record
Explore source-linked visual explanations for Arvinas. Unsupported claims are withheld while source review continues.
Record 948 · Recorded date: Needs review
What it does
Unsupported business claims are withheld pending source review. Explore the linked records for available evidence.
Explore company records →